Crosstalk Between Autophagy and Metabolism: Implications for Cell Survival in Acute Myeloid Leukemia

Overview

Journal Cell Death Discov

Date 2024 Jan 24

PMID 38267416

Authors

YongFeng Chen

Jia Chen

Zhenyou Zou

Linglong Xu

Jing Li

Affiliations

Soon will be listed here.

Abstract

Acute myeloid leukemia (AML), a prevalent form of leukemia in adults, is often characterized by low response rates to chemotherapy, high recurrence rates, and unfavorable prognosis. A critical barrier in managing refractory or recurrent AML is the resistance to chemotherapy. Increasing evidence indicates that tumor cell metabolism plays a crucial role in AML progression, survival, metastasis, and treatment resistance. Autophagy, an essential regulator of cellular energy metabolism, is increasingly recognized for its role in the metabolic reprogramming of AML. Autophagy sustains leukemia cells during chemotherapy by not only providing energy but also facilitating rapid proliferation through the supply of essential components such as amino acids and nucleotides. Conversely, the metabolic state of AML cells can influence the activity of autophagy. Their mutual coordination helps maintain intrinsic cellular homeostasis, which is a significant contributor to chemotherapy resistance in leukemia cells. This review explores the recent advancements in understanding the interaction between autophagy and metabolism in AML cells, emphasizing their roles in cell survival and drug resistance. A comprehensive understanding of the interplay between autophagy and leukemia cell metabolism can shed light on leukemia cell survival strategies, particularly under adverse conditions such as chemotherapy. This insight may also pave the way for innovative targeted treatment strategies.

Citing Articles

Lysosome targeted therapies in hematological malignancies.

Manivannan M, Peters A, Gibson S Front Oncol. 2025; 15:1549792.

PMID: 40066097 PMC: 11891156. DOI: 10.3389/fonc.2025.1549792.

Cancer statistics, 2025.

Siegel R, Kratzer T, Giaquinto A, Sung H, Jemal A CA Cancer J Clin. 2025; 75(1):10-45.

PMID: 39817679 PMC: 11745215. DOI: 10.3322/caac.21871.

Prediction of acute myeloid leukemia prognosis based on autophagy features and characterization of its immune microenvironment.

Zhu C, Feng X, Tong L, Mu P, Wang F, Quan W Front Immunol. 2024; 15:1489171.

PMID: 39650664 PMC: 11621098. DOI: 10.3389/fimmu.2024.1489171.

Spatial metabolomics highlights metabolic reprogramming in acute myeloid leukemia mice through creatine pathway.

Bao Y, Qiao J, Gong W, Zhang R, Zhou Y, Xie Y Acta Pharm Sin B. 2024; 14(10):4461-4477.

PMID: 39525575 PMC: 11544190. DOI: 10.1016/j.apsb.2024.07.004.

Dissecting L-glutamine metabolism in acute myeloid leukemia: single-cell insights and therapeutic implications.

Chen Y J Transl Med. 2024; 22(1):1002.

PMID: 39506790 PMC: 11539756. DOI: 10.1186/s12967-024-05779-3.

References

Rabanal-Ruiz Y, Otten E, Korolchuk V . mTORC1 as the main gateway to autophagy. Essays Biochem. 2017; 61(6):565-584. PMC: 5869864. DOI: 10.1042/EBC20170027. View

Xie Y, Lei X, Zhao G, Guo R, Cui N . mTOR in programmed cell death and its therapeutic implications. Cytokine Growth Factor Rev. 2023; 71-72:66-81. DOI: 10.1016/j.cytogfr.2023.06.002. View

Shi J, Fu H, Jia Z, He K, Fu L, Wang W . High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia. EBioMedicine. 2016; 14:55-64. PMC: 5161445. DOI: 10.1016/j.ebiom.2016.11.025. View

Gregory M, Nemkov T, Park H, Zaberezhnyy V, Gehrke S, Adane B . Targeting Glutamine Metabolism and Redox State for Leukemia Therapy. Clin Cancer Res. 2019; 25(13):4079-4090. PMC: 6642698. DOI: 10.1158/1078-0432.CCR-18-3223. View

Lapa B, Goncalves A, Jorge J, Alves R, Pires A, Abrantes A . Acute myeloid leukemia sensitivity to metabolic inhibitors: glycolysis showed to be a better therapeutic target. Med Oncol. 2020; 37(8):72. DOI: 10.1007/s12032-020-01394-6. View

Kumar B, Garcia M, Weng L, Jung X, Murakami J, Hu X . Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion. Leukemia. 2017; 32(3):575-587. PMC: 5843902. DOI: 10.1038/leu.2017.259. View

Wang Y, Israelsen W, Lee D, Yu V, Jeanson N, Clish C . Cell-state-specific metabolic dependency in hematopoiesis and leukemogenesis. Cell. 2014; 158(6):1309-1323. PMC: 4197056. DOI: 10.1016/j.cell.2014.07.048. View

Willems L, Jacque N, Jacquel A, Neveux N, Trovati Maciel T, Lambert M . Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood. 2013; 122(20):3521-32. PMC: 3829119. DOI: 10.1182/blood-2013-03-493163. View

Patra S, Elahi N, Armorer A, Arunachalam S, Omala J, Hamid I . Mechanisms Governing Metabolic Heterogeneity in Breast Cancer and Other Tumors. Front Oncol. 2021; 11:700629. PMC: 8495201. DOI: 10.3389/fonc.2021.700629. View

10.

Huang L, Lin L, Fu X, Meng C . Development and validation of a novel survival model for acute myeloid leukemia based on autophagy-related genes. PeerJ. 2021; 9:e11968. PMC: 8364747. DOI: 10.7717/peerj.11968. View

11.

Ji Q, Ding Y, Sun Y, Zhang Y, Gao H, Song H . Antineoplastic effects and mechanisms of micheliolide in acute myelogenous leukemia stem cells. Oncotarget. 2016; 7(40):65012-65023. PMC: 5323134. DOI: 10.18632/oncotarget.11342. View

12.

Fu Y, Liu S, Yin S, Niu W, Xiong W, Tan M . The reverse Warburg effect is likely to be an Achilles' heel of cancer that can be exploited for cancer therapy. Oncotarget. 2017; 8(34):57813-57825. PMC: 5593685. DOI: 10.18632/oncotarget.18175. View

13.

Chen T, Zhang J, Zeng H, Zhang Y, Zhang Y, Zhou X . Antiproliferative effects of L-asparaginase in acute myeloid leukemia. Exp Ther Med. 2020; 20(3):2070-2078. PMC: 7401243. DOI: 10.3892/etm.2020.8904. View

14.

Stallon Illangeswaran R, Jebanesan D, Sivakumar K, Vidhyadharan R, Rajamani B, Janet N . Chemotherapeutic drugs elicit stemness and metabolic alteration to mediate acquired drug-resistant phenotype in acute myeloid leukemia cell lines. Leuk Res. 2023; 128:107054. DOI: 10.1016/j.leukres.2023.107054. View

15.

Cao Y, Zhang A, Cai J, Yuan N, Lin W, Liu S . Autophagy regulates the cell cycle of murine HSPCs in a nutrient-dependent manner. Exp Hematol. 2014; 43(3):229-42. DOI: 10.1016/j.exphem.2014.11.002. View

16.

Mortensen M, Soilleux E, Djordjevic G, Tripp R, Lutteropp M, Sadighi-Akha E . The autophagy protein Atg7 is essential for hematopoietic stem cell maintenance. J Exp Med. 2011; 208(3):455-67. PMC: 3058574. DOI: 10.1084/jem.20101145. View

17.

Ye H, Adane B, Khan N, Sullivan T, Minhajuddin M, Gasparetto M . Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche. Cell Stem Cell. 2016; 19(1):23-37. PMC: 4938766. DOI: 10.1016/j.stem.2016.06.001. View

18.

Li W, He P, Huang Y, Li Y, Lu J, Li M . Selective autophagy of intracellular organelles: recent research advances. Theranostics. 2021; 11(1):222-256. PMC: 7681076. DOI: 10.7150/thno.49860. View

19.

Baker F, Polat I, Abou-El-Ardat K, Alshamleh I, Thoelken M, Hymon D . Metabolic Rewiring Is Essential for AML Cell Survival to Overcome Autophagy Inhibition by Loss of ATG3. Cancers (Basel). 2021; 13(23). PMC: 8657081. DOI: 10.3390/cancers13236142. View

20.

Piya S, Kornblau S, Ruvolo V, Mu H, Ruvolo P, McQueen T . Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia. Blood. 2016; 128(9):1260-9. PMC: 5009514. DOI: 10.1182/blood-2016-01-692244. View